Normally when I sit down to prepare the editor’s desk, I read through the articles we are featuring and think about what happened in the past week in the world of diabetes and healthcare; then I fashion my comments to encourage you to read our entire newsletter. This week I don’t …

Study announces a new benefit in addition to reductions in major adverse cardiovascular events.

Does liraglutide help in the reduction of cardiovascular diseases?

Alogliptin is efficient and safe in the management of type 2 diabetes even in patients who have cardiovascular disease as a comorbidity.

Is semaglutide a better way to manage type 2 diabetes?

During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes were assigned to the intensive treatment arm (received a sulfonylurea or insulin, or metformin if overweight) or a conventional treatment arm (dietary interventions only). In the intensive treatment arm, which one of the following benefits became apparent only when a 10-year follow-up study was conducted? A. Reduced risk of microvascular complications B. Clinically lower overall BMI C. Reduced risk of myocardial infarction D. Lower overall mean A1C Did you get it right? Follow the link to find out!

Dr. Jovanovic discusses pregancy and prediabetes, and how women's chance of developing type 2 in the future increases after gestational diabetes.

Dr. Jovanovic discusses A1C goals for pregnancy, and how proper A1c control is essential for the health of mother and baby.

Dr. Jovanovic discusses the safety of diabetes medications during pregnancy, and advocates that insulin is the only treatment that is truly safe.

Dr. Jovanovic discusses hyperglycemia in pregnancy, also known as gestational diabetes, and why all pregnant women should be tested for glucose tolerance.